In studies investigating the combination of two or more anticancer drugs that are already approved for independent use, or 'maintenance' regimens, the use of progression-free survival as the end point for approval is inadequate; sequential treatment with the same agents or existing salvage therapies, respectively, might provide an equivalent survival benefit, with lower toxicity, cost, and treatment burden, therefore, the use of an overall survival end point is essential to justify such interventions.
This is a preview of subscription content, access via your institution
Subscribe to Nature+
Get immediate online access to Nature and 55 other Nature journal
Subscribe to Journal
Get full journal access for 1 year
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Prasad, V., Kim, C., Burotto, M. & Vandross, A. The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses. JAMA Intern. Med. 175, 1389–1398 (2015).
Booth, C. M. & Eisenhauer, E. A. Progression-free survival: meaningful or simply measurable? J. Clin. Oncol. 30, 1030–1033 (2012).
Mailankody, S. & Prasad, V. Five years of cancer drug approvals: innovation, efficacy, and costs. JAMA Oncol. 1, 539–540 (2015).
Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23–34 (2015).
Hanna, N. H. et al. Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study. Ann. Oncol. 13, 95–102 (2002).
Goodwin, J. S. Routine cancer antigen 125 surveillance — the fatal attraction of testing. JAMA Oncol. 2, 1412–1413 (2016).
Moskowitz, C. H. et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 385, 1853–1862 (2015).
Sweetenhan, J. W. et al. Updated efficacy and safety data from the AETHERA trial of consolidation with brentuximab vedotin after autologous stem cell transplant (ASCT) in Hodgkin lymphoma patients at high risk of relapse [abstract]. Biol. Blood Marrow Transplant. 22, S36 (2016).
The authors declare no competing financial interests.
About this article
Cite this article
Gyawali, B., Prasad, V. Combining drugs and extending treatment — a PFS end point is not sufficient. Nat Rev Clin Oncol 14, 521–522 (2017). https://doi.org/10.1038/nrclinonc.2017.72
This article is cited by
Nature Reviews Clinical Oncology (2022)
Nature Biotechnology (2021)
Nature Reviews Clinical Oncology (2019)